Needham & Company Maintains a'Buy' on Æterna Zentaris (AEZS); Discussion with Management

Needham & Company maintains a'Buy' on Æterna Zentaris (NASDAQ: AEZS)

Needham analyst said, "Last week, we had an informative discussion with the Company management, and the message was quite clear: the Company is well on track for a series of potential value inflection events in 2H11. For perifosine, enrollment in pivotal X-PECT trial in mCRC is expected to complete in July, with data expected to be reported in 4Q11/1Q12: we are positively inclined towards the Phase 3 X-PECT trial of perifosine in CRC conducted by partner Keryx, based on strong data from Phase 2 RCT and a Phase 3 trial sufficiently powered for evaluating an effect on overall survival. For AEZS-130, data in a pivotal trial on the adult growth hormone deficiency (AGHD) diagnostic are expected mid-2011 with an FDA submission planned in 2H11: we favor AEZS-130 as a near-term commercial opportunity that may provide steady cash flow to the Company. For AEZS-108, we note encouraging Phase 2 data in endometrial cancer and a plan to enter pivotal testing."

For more ratings news on Æterna Zentaris click here and for the rating history of Æterna Zentaris click here.

Shares of Æterna Zentaris closed at $2.21 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Coherent (COHR) PT Raised to $420 at Needham
• Needham Reiterates Buy Rating on Cerebras Systems (CBRS)
• NANO Nuclear Announces Participation in Several Investor Conferences